In this phase 3 , observer-blind , randomised controlled trial , university students aged 18-24 years from ten sites in England were randomly assigned ( 1:1:1 , block size of three ) to receive two doses 1 month apart of Japanese Encephalitis vaccine ( controls ) , 4CMenB , or one dose of MenACWY-CRM then placebo .